The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes

被引：0
|
作者：
Nauck, M. A. [1 ]
Petrie, J. R. [2 ]
Sesti, G. [3 ]
Mannucci, E. [4 ]
Courreges, J-P [5 ]
Atkin, S. [6 ]
Duering, M. [7 ]
Jensen, C. B. [7 ]
Heller, S. [8 ]
机构：
[1] Ctr Diabet, Bad Lauterberg Im Harz, Germany
[2] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[3] Magna Graecia Univ Catanzaro, Catanzaro, Italy
[4] Careggi Teaching Hosp, Florence, Italy
[5] Gen Hosp, Narbonne, France
[6] Hull York Med Sch, Kingston Upon Hull, N Humberside, England
[7] Novo Nordisk, Soborg, Denmark
[8] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [41] In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
    Lipscombe, Lorraine L.
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (04) : JC16 - JC16
  • [42] Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
    Wilkinson, Lars
    Hunt, Barnaby
    Johansen, Pierre
    Iyer, Neeraj N.
    Tam Dang-Tan
    Pollock, Richard F.
    DIABETES THERAPY, 2018, 9 (03) : 951 - 961
  • [43] Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
    Lars Wilkinson
    Barnaby Hunt
    Pierre Johansen
    Neeraj N. Iyer
    Tam Dang-Tan
    Richard F. Pollock
    Diabetes Therapy, 2018, 9 : 951 - 961
  • [44] Effectiveness and tolerability of once-weekly GLP-1 receptor agonists in clinical practice: a focus on switching between once-weekly molecules in type 2 diabetes
    Formoso, G.
    Di Dalmazi, G.
    Coluzzi, S.
    Baldassarre, M. P. A.
    Ghit, A.
    Graziano, G.
    Rossi, M. C.
    Ciappini, B.
    Milo, M.
    Carrieri, F.
    Nicolucci, A.
    Consoli, A.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S314 - S314
  • [45] Taspoglutide, a once-weekly human GLP-1 analogue, is superior to Sitagliptin in improving glycaemic control and achieving weight loss in patients with type 2 diabetes: the T-emerge 4 Trial
    Chiasson, J. -L
    Leiter, L. A.
    Forti, A.
    Bergenstal, R. M.
    Woloschak, M.
    Boldrin, M.
    Balena, R.
    DIABETOLOGIA, 2010, 53
  • [46] Tolerability, Safety, and Pharmacokinetics of Once-Weekly Administration of GLP-1 Analogue in Healthy Subjects
    Xu, Michael M.
    DIABETES, 2015, 64 : A72 - A73
  • [47] Taspoglutide, a Novel Human Once-Weekly GLP-1 Analogue, Improves β-Cell Survival in ZDF Rats
    Uhles, Sabine
    Brecheisen, Mathieu
    Benardeau, Agnes
    Wang, Haiyan
    Tobalina, Lola
    Wollheim, Claes B.
    Sewing, Sabine
    Migliorini, Cristiano
    Sebokova, Elena
    DIABETES, 2010, 59 : A148 - A148
  • [48] Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?
    Strong, Jodi
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S19 - S28
  • [49] In Vivo Effect of Semaglutide in Pigs Supports Its Potential as a Long-Acting GLP-1 Analogue for Once-Weekly Dosing
    Rolin, Bidda
    Larsen, Marianne O.
    Christoffersen, Berit O.
    Lau, Jesper
    Knudsen, Lotte B.
    DIABETES, 2015, 64 : A287 - A287
  • [50] Canagliflozin provides reductions in HbA1c, body weight, and blood pressure in patients with type 2 diabetes on metformin with or without other antihyperglycaemic agents
    Hollander, P.
    Mathieu, C.
    Tong, C.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2015, 58 : S352 - S352
12345